Santhera Pharmaceuticals Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Santhera Pharmaceuticals Holding şirketinin toplam hissedar öz sermayesi CHF48.1M ve toplam borcu CHF23.7M olup, bu da borç-öz sermaye oranını 49.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CHF108.2M ve CHF60.2M dir. Santhera Pharmaceuticals Holding 'in FAVÖK'ü CHF53.7M faiz karşılama oranı 3.3 dur. Şirketin CHF16.5M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

49.2%

Borç/özkaynak oranı

CHF 23.67m

Borç

Faiz karşılama oranı	3.3x
Nakit	CHF 16.49m
Eşitlik	CHF 48.06m
Toplam yükümlülükler	CHF 60.19m
Toplam varlıklar	CHF 108.25m

Son finansal sağlık güncellemeleri

Recent updates

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

Jun 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SANN 'nin kısa vadeli varlıkları ( CHF33.6M ) kısa vadeli yükümlülüklerini ( CHF53.1M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: SANN şirketinin kısa vadeli varlıkları ( CHF33.6M ) uzun vadeli yükümlülüklerini ( CHF7.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SANN 'nin net borç/öz sermaye oranı ( 14.9% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: SANN 'nin borç/öz sermaye oranı son 5 yılda 649.6% seviyesinden 49.2% seviyesine düştü.

Borç Kapsamı: SANN 'nin borcu işletme nakit akışı ( 200.1% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: SANN 'in borcuna ilişkin faiz ödemeleri EBIT ( 3.3 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Santhera Pharmaceuticals Holding Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Recent updates

Santhera Pharmaceuticals Announces Positive Topline Results from LIONHEART Study with AGAMREE®? (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

First half 2024 earnings released: CHF1.35 loss per share (vs CHF2.09 loss in 1H 2023)

Santhera Pharmaceuticals Holding AG to Report First Half, 2024 Results on Sep 12, 2024

Santhera Pharmaceuticals Holding AG Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary of Santhera Pharmaceuticals AG, Effective August 1, 2024

The Market Doesn't Like What It Sees From Santhera Pharmaceuticals Holding AG's (VTX:SANN) Revenues Yet

New minor risk - Market cap size

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on May 31, 2024

Third quarter 2023 earnings released

Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Grants Priority Review by China's NMPA

New minor risk - Financial data availability

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

Santhera Pharmaceuticals Holding AG, Annual General Meeting, May 28, 2024

New major risk - Financial position

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Santhera Pharmaceuticals Holding AG Launches AGAMREE (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Promotes Promotion of Geert Jan Van Daal to Chief Commercial Officer and of Marc Schrader to Chief Technology Officer

Santhera Pharmaceuticals Receives U.S. FDA Approval of Agamree(R) (vamorolone) for the Treatment of Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of AGAMREE®? (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy

New minor risk - Market cap size

First half 2023 earnings released: CHF2.09 loss per share (vs CHF5.24 loss in 1H 2022)

Chiesi Farmaceutici S.p.A. acquired Raxone®/idebenone business worldwide from Santhera Pharmaceuticals Holding AG (SWX:SANN).

Santhera Pharmaceuticals Holding AG to Report First Half, 2023 Results on Sep 07, 2023

Forecast breakeven date moved forward to 2023

Santhera Pharmaceuticals Holding AG announced that it expects to receive $14.999996 million in funding from Catalyst

Full year 2022 earnings released

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Apr 26, 2023

Santhera and Reveragen Announces FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy

Insufficient new directors

European Medicines Agency Validates Santhera Pharmaceuticals Holding AG’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy

First half 2022 earnings released: CHF0.52 loss per share (vs CHF0.92 loss in 1H 2021)

Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding Ag Submits Marketing Authorization Application to the European Medicines Agency for Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG to Report First Half, 2022 Results on Oct 31, 2022

Forecast to breakeven in 2024

Santhera Pharmaceuticals Publishes Positive Pivotal Clinical Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG and ReveraGen Announce First Participant Dosed in FDA-funded Phase 2 Pilot Study with Vamorolone in Becker Muscular Dystrophy

Santhera Pharmaceuticals Holding AG Announces Board Changes

Santhera Pharmaceuticals Holding AG Updates on Ongoing NDA Submission for Vamorolone

Santhera Pharmaceuticals Holding AG Announces that Elmar Schnee will not stand for re-election at the upcoming Annual General Meeting

Santhera Pharmaceuticals Holding AG Auditor Raises 'Going Concern' Doubt

Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference

Santhera Pharmaceuticals Holding AG, Annual General Meeting, Jun 29, 2022

Insufficient new directors

Santhera Pharmaceuticals Holding AG Appoints Shabir Hasham as Chief Medical Officer and a Member of Santhera’s Executive Management Team, Effective May 1, 2022

Santhera Pharmaceuticals and Reveragen Biopharma, Inc Announces Initiation of Rolling New Drug Application Submission to U.S. Food and Drug Administration

Price target increased to CHF7.00

Forecast to breakeven in 2024

Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in funding from Highbridge Capital Management, LLC

Price target decreased to CHF4.75

First half 2021 earnings released: CHF0.92 loss per share (vs CHF2.78 loss in 1H 2020)

Santhera Pharmaceuticals Holding AG announced that it expects to receive CHF 35 million in funding from Idorsia Pharmaceuticals Ltd., Highbridge Capital Management, LLC, Waypoint Capital and other investors

Santhera Pharmaceuticals and ReveraGen BioPharma, Inc. to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference

Santhera Pharmaceuticals Holding AG Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy

Consensus revenue estimates increase to CHF16.8m

Price target increased to CHF6.23

Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study

Executive VP, Chief Medical Officer & Head of Development has left the company

Santhera Pharmaceuticals and ReveraGen Biopharma Announce New 2.5-Year Treatment Data with Vamorolone in Duchenne Muscular Dystrophy

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Completion of First 6-Month Period of Pivotal VISION-DMD Trial with Vamorolone in Duchenne Muscular Dystrophy

Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial

Santhera Pharmaceuticals Holding AG to Report Fiscal Year 2020 Final Results on Apr 27, 2021

New 90-day high: CHF3.20

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Pharmaceuticals Holding AG has completed a Follow-on Equity Offering.

Santhera Announces Departure of Kristina Sjöblom Nygren, Chief Medical Officer and Head of Development

New 90-day low: CHF3.29

Analysts increase EPS estimates to -CHF3.25

Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa® in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone

New 90-day low: CHF6.22

Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy

First half earnings released

Santhera Pharmaceuticals Holding AG to Report First Half, 2020 Results on Sep 08, 2020

New 90-day low - CHF6.44